Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Will GSK’s China Scandals Diminish Big Pharma’s Interest in China R&D?

publication date: Jul 12, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Because of scandals in China – first a retraction of a scientific article, then the bribery accusations – GlaxoSmithKline’s China operations have cast a pall over the entire company’s reputation. An even larger question is whether the company’s problems will spill over to affect other multinational pharmas that are also operating in China. In particular, will Glaxo’s misfortunes deal a blow to R&D in China? According to Greg B. Scott, CEO of ChinaBio®, "If something like the scientific retraction had occurred in the US or Europe, the company involved would just have said that a researcher made an error,” Scott said. “But it happened in China, so it affects the perception of the whole country." More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...